Abstract:OBJECTIVE:In recent years, the combination of cetuximab and chemoradiotherapy (CRT) has been used to treat stage III non-small cell lung cancer (NSCLC); however, limited data are available for Chinese patients. Herein, we report preliminary data from a phase I/II study testing the combination of cetuximab with inductive chemotherapy, followed by concurrent CRT (CCRT) in Chinese patients with stage III NSCLC.METHODS:Eligibility criteria were Zubrod performance status (PS) 0-1, forced expiratory volume in 1 second (FEV1) ≥1.2 L and adequate organ function. Enrolled patients received weekly cetuximab (initial dose of 400 mg/m(2) on day 1 of week 1 and a maintenance dose of 250 mg/m(2) on week 2 to the end of CCRT) with cisplatin/vinorelbine (NP) chemotherapy (every 3 weeks for 2 cycles from week 2, followed by two cycles of concomitant NP chemotherapy and intensity-modulated thoracic radiotherapy (TRT) (60-66 Gy/2 Gy). The primary endpoints were toxicity and feasibility. All patients received positron emission tomography-computerized tomography (PET-CT) scans within the 2 weeks prior to enrollment. Univariate analyses were used to assess the correlation between SUV-T, SUV-N, SUV-TOTAL, gender, age, histology, tumor-node-metastasis (TNM) stage, PS and smoking status and survival. Survival curves were generated for different populations using the Kaplan-Meier method and compared using a log-rank test.RESULTS:Seventeen patients were enrolled and 16 completed the full regime. The overall response rate (ORR) was 58.8% and 82.3% after the induction and CCRT phases, respectively. With a median follow-up duration of 27.6 months, the median survival was 27.6 months [95% confidence interval (CI): 11.3-43.9 months] with 1- and 2-year survival rates of 88.2% (95% CI, 60.6-96.9%) and 58.8% (95% CI, 60.6-77.8%), respectively. Three patients remain progression-free to date, and the median progression-free survival (PFS) was 13.5 months (95% CI, 6.8-20.2 months). No treatment-related death occurred; however, 76% of the patients experienced grade 3+ adverse events (AEs), including nausea/vomiting, intestinal obstruction, and esophagitis (<6%), while other AEs were mostly of hematological nature (71%). The cut-off values for SUV-T and SUV-TOTAL were 11 and 20, respectively. Univariate analyses revealed SUV-TOTAL (P=0.027), SUV-T (P=0.025), and PS (P=0.006) as potential survival predictors, with a hazard ratio (HR) of 3.4, 3.7, and 9.9, respectively.CONCLUSIONS:The combination of cetuximab with induction chemotherapy followed by CCRT appears feasible and promising. Local and locoregional maximal SUVs, defined by (18)F-FDG PET-CT scanning, may represent a prognostic indicator for long-term survival for these patients, which warrants further study.

Feasibility of Omitting the Clinical Target Volume under PET-CT Guidance in Unresectable Stage III Non-Small-cell Lung Cancer: A Phase II Clinical Trial

Feasibility of Omitting Clinical Target Volume for Limited-Disease Small Cell Lung Cancer Treated with Chemotherapy and Intensity-Modulated Radiotherapy

Retrospective analysis of omitting clinical target volume for patients with stage Ⅲ non-small cell lung cancer treated with intensity-modulated radiotherapy

Efficacy of the Smaller Target Volume for Stage III Non-Small Cell Lung Cancer Treated with Intensity-Modulated Radiotherapy.

Computed Tomography Fluoroscopy-Guided Percutaneous 125I Seed Implantation for Safe, Effective and Real-Time Monitoring Radiotherapy of Inoperable Stage T1-3N0M0 Non-Small-cell Lung Cancer.

Retrospective clinical study of simultaneous reduced dose in clinical target volume of radical intensity-modulated radiotherapy for treatment of stage III non-small-cell lung cancer

Efficacy Fi Cacy and Toxicity of Moderately Hypofractionated Radiation Therapy with Helical TomoTherapy Versus Conventional Radiation Therapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer Receiving Concurrent Chemotherapy: A Multicenter, Randomized Phase 3 Trial

Feasibility and Efficacy of Helical Intensity-Modulated Radiotherapy for Stage III Non-Small Cell Lung Cancer in Comparison with Conventionally Fractionated 3D-CRT.

Efficacy and Toxicity of Moderately Hypofractionated Radiotherapy with Helical TomoTherapy Versus Conventional Radiotherapy in Patients with Unresectable Stage III Non–Small-Cell Lung Cancer Receiving Concurrent Chemotherapy: A Multicentre, Randomized Phase III Trial

Omitting Elective Nodal Irradiation and Irradiating Postinduction Versus Preinduction Chemotherapy Tumor Extent for Limited‐stage Small Cell Lung Cancer

Positron Emission Tomography-Guided Bone Marrow-Sparing Radiation Therapy for Locoregionally Advanced Cervix Cancer: Final Results From the INTERTECC Phase II/III Trial

Safety and Efficacy of Hypofractionated Radiotherapy and Concurrent Chemotherapy in Unresectable Stage III Non-Small-Cell Lung Cancer

Protocol for the isotoxic intensity modulated radiotherapy (IMRT) in stage III non-small cell lung cancer (NSCLC): a feasibility study

The Prognosis and Feasibility of Extensive Clinical Target Volume in Postoperative Radiotherapy for Esophageal Squamous Cell Carcinoma: A Phase II Clinical Trial

Omitting elective nodal irradiation and irradiating postinduction versus preinduction chemotherapy tumor extent for limited-stage small cell lung cancer: interim analysis of a prospective randomized noninferiority trial.

Correction: Efficacy and toxicity of stereotactic body radiotherapy for un-resectable stage III non-small cell lung cancer patients unfit for concurrent chemoradiation therapy: a retrospective study

Three-Dimensional Radiation Therapy to the Primary Tumor with Concurrent Chemotherapy in Patients with Stage IV Non-Small Cell Lung Cancer: Results of a Multicenter Phase 2 Study from PPRA-RTOG, China

Feasibility of Cetuximab and Chemoradiotherapy Combination in Chinese Patients with Unresectable Stage III Non-Small Cell Lung Cancer: a Preliminary Report.

Outcomes of Hypofractional Tomotherapy in Patients with Stage III Nonsmall Cell Lung Cancer Who Are Not Eligible for Surgery or Concurrent Chemoradiation

Neoadjuvant Hypofractionated Radiotherapy Combined with Pembrolizumab Plus Chemotherapy for Potentially Resectable Non-Small Cell Lung Cancer: A Phase Ib Study.

Concomitant Chemoradiotherapy Using Pemetrexed and Carboplatin for Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC): Preliminary Results of a Phase II Study